Medibank shares remain in limbo after customer data hack confirmed

Hackers claim to have taken 200GB of customer data from Medibank…

Medibank Private Ltd (ASX: MPL) shares won't be going anywhere today.

This afternoon, Australia's largest private health insurance provider released another update on its cyber incident.

Unfortunately, things have continued to get worse for Medibank and it has requested that it shares remain halted until the matter is resolved.

A man sits in casual clothes in front of a computer amid graphic images of data superimposed on the image, as though he is engaged in IT or hacking activities.

Image source: Getty Images

What's going on?

As readers may be aware, last week Medibank revealed that it had detected unusual activity on its network. At the time it didn't believe that customer data had been taken from its systems.

However, last night the company advised that it had received messages from a group claiming to have removed customer data and wanting to negotiate a ransom for it.

This afternoon, Medibank revealed that this group has claimed to have taken 200GB of customer data from its systems.

As proof, the group has provided a sample of the data to Medibank. That data includes names, addresses, dates of birth, Medicare numbers, policy numbers, phone numbers, and some claims data. The latter includes the location of where a customer received medical services, and codes relating to their diagnosis and procedures.

Other data that the group claims to have taken includes data related to credit card security. Though, this has not been confirmed by its investigations.

However, given that Medibank's team (worryingly) couldn't even tell that 200GB of data had been taken from its systems last week, it may be prudent to assume that what the group is saying is accurate about credit card data.

Given the nature of the information that has been taken, Medibank advised that it is in discussions with government stakeholders about what it can do to assist its customers in safeguarding their identities and health information.

Medibank's CEO, David Koczkar, added:

I unreservedly apologise for this crime which has been perpetrated against our customers, our people, and the broader community. I know that many will be disappointed with Medibank and I acknowledge that disappointment.

This cybercrime is now the subject of an investigation by the Australian Federal Police. We will learn from this incident and will share our learnings with others. Medibank will remain open and transparent and will continue to provide comprehensive updates as often as we can and need to.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor with stethoscope typing on her computer.
Healthcare Shares

Is the ResMed share price a cheap buy?

I look at what the next few years of earnings growth could mean for today’s valuation.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Expert names 'undervalued' ASX 200 healthcare stock to buy today

A top fundie expects more outperformance from this resurgent ASX healthcare share.

Read more »

A gavel is placed on a stand on a desk with a legal representative wearing a suit in the background.
Healthcare Shares

Cochlear shares fall as investors face another setback

Cochlear shares are back in the red.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Is the Medibank share price a buy for its 6% dividend yield?

This business is offering very healthy dividends.

Read more »

Senior man looking at his laptop and pondering something.
Healthcare Shares

Could Mesoblast shares rise over 100% in 12 months?

Bell Potter has given its view on this stock.

Read more »

Two scientists analysing results on a computer screen.
Healthcare Shares

$10,000 invested in Pro Medicus and CSL shares 3 years ago is now worth…

Was I better off investing $10,000 into Pro Medicus or CSL shares three years ago?

Read more »

A share market investment manager monitors share price movements on his mobile phone and laptop
Healthcare Shares

Fund managers are loading up on CSL shares. Here's why

CSL is attracting renewed interest from fundies.

Read more »

Happy businessman fist pumping while looking at a tablet.
Healthcare Shares

Mesoblast wins FDA nod for new Ryoncil potency test

Mesoblast gets FDA approval for a new Ryoncil potency assay, aiming to ensure quality and support product expansion.

Read more »